US President Donald Trump has announced a new tariff strategy, in addition to his country-by-country letters to world leaders, aimed at boosting domestic manufacturing and national security. The plan includes pharmaceutical tariffs, which are expected to be implemented by the end of the month.
Trump’s dual approach is authorized by two different laws: Section 232 tariffs, named after a part of a 1962 trade law, and IEEPA tariffs, under the International Emergency Economic Powers Act. These tariffs cover various products and are designed to bolster national security, although some experts argue that this aim may be flawed.
Prior to Trump’s presidency, Section 232 tariffs were rarely used. However, he has employed them extensively, with currently two sets in place and nine more under investigation. The first step in imposing these tariffs is a Commerce Department investigation, which focuses on national security concerns.
Critics argue that the tariffs are too broad and may not be an effective way to boost domestic manufacturing. They suggest alternative methods, such as subsidies, might be more efficient. Additionally, some experts believe that imposing global Section 232 tariffs could negatively impact national security by increasing costs for allies and reducing cooperation.
The Trump administration maintains that domestic manufacturing is essential for national security, but experts warn of the potential risks and unintended consequences of this approach. As the situation unfolds, it remains to be seen whether this dual tariff strategy will yield desired results or create further global trade tensions.
Source: https://www.npr.org/2025/07/18/nx-s1-5452431/trump-tariffs-section-232